CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Teva Pharma Ind Adr Rep 1 - TEVA CFD

10.00
1.67%
Market Trading Hours* (UTC) Opens on Thursday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Teva Pharmaceutical Industries Ltd ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 10.17
Open* 10.15
1-Year Change* 32.51%
Day's Range* 9.83 - 10.15
52 wk Range 7.09-11.45
Average Volume (10 days) 6.04M
Average Volume (3 months) 207.39M
Market Cap 10.46B
P/E Ratio -100.00K
Shares Outstanding 1.12B
Revenue 15.02B
EPS -2.00
Dividend (Yield %) N/A
Beta 1.18
Next Earnings Date Nov 1, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 26, 2023 10.17 0.00 0.00% 10.17 10.37 10.16
Sep 25, 2023 10.23 -0.05 -0.49% 10.28 10.28 10.01
Sep 22, 2023 10.33 0.03 0.29% 10.30 10.51 10.14
Sep 21, 2023 10.31 -0.27 -2.55% 10.58 10.60 10.30
Sep 20, 2023 10.68 0.33 3.19% 10.35 10.69 10.35
Sep 19, 2023 10.27 -0.26 -2.47% 10.53 10.54 10.24
Sep 18, 2023 10.53 0.04 0.38% 10.49 10.63 10.49
Sep 15, 2023 10.55 0.04 0.38% 10.51 10.63 10.51
Sep 14, 2023 10.54 0.22 2.13% 10.32 10.56 10.28
Sep 13, 2023 10.32 0.31 3.10% 10.01 10.33 10.00
Sep 12, 2023 10.02 0.00 0.00% 10.02 10.11 9.96
Sep 11, 2023 10.02 0.31 3.19% 9.71 10.02 9.71
Sep 8, 2023 9.60 0.25 2.67% 9.35 9.63 9.35
Sep 7, 2023 9.32 -0.02 -0.21% 9.34 9.36 9.24
Sep 6, 2023 9.46 -0.04 -0.42% 9.50 9.51 9.37
Sep 5, 2023 9.53 -0.22 -2.26% 9.75 9.76 9.52
Sep 1, 2023 9.81 0.00 0.00% 9.81 9.90 9.77
Aug 31, 2023 9.74 0.15 1.56% 9.59 9.83 9.58
Aug 30, 2023 9.66 -0.04 -0.41% 9.70 9.76 9.66
Aug 29, 2023 9.72 0.12 1.25% 9.60 9.78 9.59

Teva Pharma Ind Adr Rep 1 Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 14925 15878 16659 16887 18854
Revenue 14925 15878 16659 16887 18854
Cost of Revenue, Total 7487 8014 8870 9351 10558
Gross Profit 7438 7864 7789 7536 8296
Total Operating Expense 17024 14162 20231 17330 20537
Selling/General/Admin. Expenses, Total 3445 3402 3519 3667 4052
Research & Development 838 967 997 1010 1213
Unusual Expense (Income) 5239 1721 6739 3191 4838
Other Operating Expenses, Total 15 -41 -20 -28 -286
Operating Income -2099 1716 -3572 -443 -1683
Interest Income (Expense), Net Non-Operating -904 -988 -833 -825 -894
Other, Net -62 -70 -1 3 -19
Net Income Before Taxes -3065 658 -4406 -1265 -2596
Net Income After Taxes -2427 447 -4238 -987 -2304
Minority Interest 53 -39 109 2 322
Equity In Affiliates 21 9 138 -13 -71
Net Income Before Extra. Items -2353 417 -3991 -998 -2053
Total Extraordinary Items 0 0 -97
Net Income -2353 417 -3991 -998 -2150
Total Adjustments to Net Income 1 -1 -249
Income Available to Common Excl. Extra. Items -2353 417 -3990 -999 -2302
Income Available to Common Incl. Extra. Items -2353 417 -3990 -999 -2399
Dilution Adjustment
Diluted Net Income -2353 417 -3990 -999 -2399
Diluted Weighted Average Shares 1110 1107 1095 1091 1021
Diluted EPS Excluding Extraordinary Items -2.11982 0.37669 -3.64384 -0.91567 -2.25465
Dividends per Share - Common Stock Primary Issue 0
Diluted Normalized EPS 0.94806 1.43282 0.35648 0.98547 0.82537
Depreciation / Amortization 99 126 139 162
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 3878 3661 3884 3595 3786
Revenue 3878 3661 3884 3595 3786
Cost of Revenue, Total 1959 2015 1784 1885 1958
Gross Profit 1919 1646 2100 1710 1828
Total Operating Expense 4524 3659 4739 3176 4735
Selling/General/Admin. Expenses, Total 910 842 837 777 849
Research & Development 240 234 210 175 228
Depreciation / Amortization 20 21
Unusual Expense (Income) 1448 571 1854 321 1683
Other Operating Expenses, Total -33 -3 54 -2 -4
Operating Income -646 2 -855 419 -949
Interest Income (Expense), Net Non-Operating -216 -260 -237 -230 -225
Other, Net -52 -9 -23 14
Net Income Before Taxes -914 -258 -1101 166 -1160
Net Income After Taxes -898 -239 -1255 59 -260
Minority Interest 35 33 32 -3 27
Equity In Affiliates 1 1 -1 0
Net Income Before Extra. Items -862 -206 -1222 55 -233
Net Income -862 -206 -1222 55 -233
Total Adjustments to Net Income -1 1 1 1 1
Income Available to Common Excl. Extra. Items -863 -205 -1221 56 -232
Income Available to Common Incl. Extra. Items -863 -205 -1221 56 -232
Diluted Net Income -863 -205 -1221 56 -232
Diluted Weighted Average Shares 1120 1115 1113 1119 1110
Diluted EPS Excluding Extraordinary Items -0.77054 -0.18386 -1.09704 0.05004 -0.20901
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.08375 0.16359 -0.01429 0.23651 0.77653
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 12051 12573 13005 13464 13794
Cash and Short Term Investments 2801 2165 2177 1975 1784
Cash & Equivalents 2801 2165 2177 1975 1782
Short Term Investments 2
Total Receivables, Net 3696 4529 4581 5676 5822
Accounts Receivable - Trade, Net 3696 4529 4581 5676 5822
Total Inventory 3833 3818 4403 4422 4731
Prepaid Expenses 1162 1075 945 870 899
Other Current Assets, Total 559 986 899 521 558
Total Assets 44006 47666 50640 57470 60683
Property/Plant/Equipment, Total - Net 6158 6477 6855 6950 6868
Property/Plant/Equipment, Total - Gross 11676 11718 11947 11864 11796
Accumulated Depreciation, Total -5518 -5241 -5092 -4914 -4928
Goodwill, Net 17633 20040 20624 24846 24917
Intangibles, Net 6270 7466 8923 11232 14005
Other Long Term Assets, Total 1894 1110 1233 978 1038
Total Current Liabilities 11469 11027 13164 13674 14322
Accounts Payable 1887 1686 1756 1718 1853
Accrued Expenses 2810 2880 2581 2680 2738
Notes Payable/Short Term Debt 23 23 514 514 516
Current Port. of LT Debt/Capital Leases 2086 1403 2674 1831 1700
Other Current Liabilities, Total 4663 5035 5639 6931 7515
Total Liabilities 36109 37388 40614 43498 45976
Total Long Term Debt 19103 21617 22731 24562 26691
Long Term Debt 19103 21617 22731 24562 26691
Deferred Income Tax 548 784 964 1096 2140
Minority Interest 794 966 1035 1091 1087
Other Liabilities, Total 4195 2994 2720 3075 1736
Total Equity 7897 10278 10026 13972 14707
Redeemable Preferred Stock 0
Common Stock 57 57 57 56 56
Additional Paid-In Capital 27688 27561 27443 27312 27210
Retained Earnings (Accumulated Deficit) -12882 -10529 -10946 -6956 -5958
Treasury Stock - Common -4128 -4128 -4128 -4128 -4142
Unrealized Gain (Loss) 0 0 0 1
Other Equity, Total -2838 -2683 -2400 -2312 -2460
Total Liabilities & Shareholders’ Equity 44006 47666 50640 57470 60683
Total Common Shares Outstanding 1110.9 1103.33 1096.51 1092.19 1089.39
Total Preferred Shares Outstanding 0 0 0
Long Term Investments 61
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 11501 12051 11453 12164 12451
Cash and Short Term Investments 2143 2801 2225 2058 2175
Cash & Equivalents 2143 2801 2225 2058 2175
Total Receivables, Net 3435 3696 3730 4471 4253
Accounts Receivable - Trade, Net 3435 3696 3730 4471 4253
Total Inventory 4118 3833 3859 4049 4012
Prepaid Expenses 1253 1162 1045 1052 1064
Other Current Assets, Total 552 559 594 534 947
Total Assets 43456 44006 44252 45932 47059
Property/Plant/Equipment, Total - Net 6171 6158 5990 6181 6396
Goodwill, Net 17799 17633 18433 18837 19986
Intangibles, Net 5964 6270 6393 6700 7116
Other Long Term Assets, Total 2021 1894 1983 2050 1110
Total Current Liabilities 10411 11469 11534 10996 11613
Accounts Payable 2381 1887 1635 1901 1750
Accrued Expenses 2699 2717 2537 2579 3078
Notes Payable/Short Term Debt 23 23 23 23 23
Current Port. of LT Debt/Capital Leases 1000 2086 2746 1696 2054
Other Current Liabilities, Total 4308 4756 4593 4797 4708
Total Liabilities 35595 36109 35484 36895 37715
Total Long Term Debt 19668 19103 18497 20363 20840
Long Term Debt 19668 19103 18497 20363 20840
Deferred Income Tax 550 548 503 532 666
Minority Interest 751 794 751 791 916
Other Liabilities, Total 4215 4195 4199 4213 3680
Total Equity 7861 7897 8768 9037 9344
Common Stock 57 57 57 57 57
Additional Paid-In Capital 27719 27688 27652 27625 27587
Retained Earnings (Accumulated Deficit) -13086 -12882 -11660 -11716 -11484
Treasury Stock - Common -4128 -4128 -4128 -4128 -4128
Other Equity, Total -2701 -2838 -3153 -2801 -2688
Total Liabilities & Shareholders’ Equity 43456 44006 44252 45932 47059
Total Common Shares Outstanding 1120.41 1110.9 1110.64 1110.56 1110.35
Total Preferred Shares Outstanding
Unrealized Gain (Loss)
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -2406 456 -4099 -1000 -2472
Cash From Operating Activities 1590 798 1216 748 2446
Cash From Operating Activities 1308 1330 1557 1722 1842
Deferred Taxes -1059 -120 -696 -985 -837
Non-Cash Items 2490 833 6642 1907 5736
Cash Taxes Paid 543 495 709 552 420
Cash Interest Paid 948 913 846 840 815
Changes in Working Capital 1257 -1701 -2188 -896 -1823
Cash From Investing Activities 656 1523 863 1355 1866
Capital Expenditures -548 -562 -578 -525 -651
Other Investing Cash Flow Items, Total 1204 2085 1441 1880 2517
Cash From Financing Activities -1487 -2172 -1885 -1926 -3351
Financing Cash Flow Items -118 -6 -5 -11 -57
Total Cash Dividends Paid 0 0 -52 -22
Issuance (Retirement) of Stock, Net 0
Issuance (Retirement) of Debt, Net -1369 -2166 -1880 -1863 -3272
Foreign Exchange Effects -123 -128 8 16 -142
Net Change in Cash 636 21 202 193 819
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -238 -2406 -1152 -1211 -952
Cash From Operating Activities -145 1590 617 73 -49
Cash From Operating Activities 304 1308 1002 681 323
Deferred Taxes -106 -1059 -1214 -1258 -175
Non-Cash Items 259 2490 974 949 196
Changes in Working Capital -364 1257 1007 912 559
Cash From Investing Activities 181 656 488 341 161
Capital Expenditures -139 -548 -406 -284 -157
Other Investing Cash Flow Items, Total 320 1204 894 625 318
Cash From Financing Activities -706 -1487 -776 -336 2
Financing Cash Flow Items -5 -118 -115 -40 2
Issuance (Retirement) of Debt, Net -701 -1369 -661 -296 0
Foreign Exchange Effects 12 -123 -269 -185 -62
Net Change in Cash -658 636 60 -107 52
Total Cash Dividends Paid
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Phoenix Investment and Finances Ltd Investment Advisor 3.0069 33703410 11569608 2023-06-30 MED
Ion Asset Management Israel Ltd Hedge Fund 2.9498 33063004 4872280 2023-06-30 MED
Clal Insurance Enterprises Holdings Ltd. Investment Advisor 2.8205 31614669 12779003 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 2.7298 30597449 14795 2023-06-30 LOW
Menora Mivtachim Insurance Ltd. Insurance Company 2.3712 26578560 -62658 2023-06-30 LOW
Lingotto Investment Management LLP Investment Advisor/Hedge Fund 2.1602 24213261 7121351 2023-06-30 MED
Migdal Insurance and Financial Holdings Ltd Insurance Company 2.1096 23646440 299880 2023-06-30
Rubric Capital Management LP Hedge Fund 1.67 18718362 14218556 2023-06-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.3894 15573344 -3991484 2023-06-30 LOW
Millennium Management LLC Hedge Fund 1.2517 14030069 7835223 2023-06-30 HIGH
Slate Path Capital LP Investment Advisor 1.1096 12437000 12437000 2023-06-30 MED
Capital International Investors Investment Advisor 0.8906 9982828 0 2023-06-30 LOW
Camber Capital Management LP Hedge Fund 0.7583 8500000 5500000 2023-06-30 MED
Abrams Capital, L.L.C. Hedge Fund 0.7107 7966433 0 2023-06-30 LOW
Eversept Partners, LP Hedge Fund 0.6841 7668044 1473472 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6376 7146599 394037 2023-06-30 LOW
AustralianSuper Pension Fund 0.6195 6943247 4523700 2023-06-30 LOW
Renaissance Technologies LLC Hedge Fund 0.5835 6540060 5400 2023-06-30 HIGH
Jane Street Capital, L.L.C. Research Firm 0.5538 6206988 3138239 2023-06-30 HIGH
BSN Capital Partners Ltd Investment Advisor 0.5353 6000000 6000000 2022-12-31 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Teva Company profile

Teva Pharmaceutical (TEVA) is a multinational pharmaceutical company set up in Jerusalem in 1901. The business’s primary focus is generic drugs. Teva is a world leader in specialty medicines. Teva production facilities are based in Israel, North America, South America and Europe. Their generic drugs portfolio includes over 1,000 products that represent therapeutic versions of innovative drugs. Their specialty medicines portfolio features a wide scope of treatments of the CNS disorders. The company’s shares are traded on the New York Stock Exchange (NYSE) and on the Tel Aviv Stock Exchange (TASE). To stay informed on the latest Teva Pharma share price, follow Capital.com.
Industry: Pharmaceuticals (NEC)

5 Bazel St
P O B 3190
PETAH TIKVA
49131
IL

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

BTC/USD

26,416.65 Price
+0.950% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Oil - Crude

93.27 Price
+3.580% 1D Chg, %
Long position overnight fee 0.0588%
Short position overnight fee -0.0807%
Overnight fee time 21:00 (UTC)
Spread 0.030

XRP/USD

0.51 Price
-0.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

ETH/USD

1,601.17 Price
+0.830% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading